[Alzheimer's disease-Which substances are at present in phase III studies?]
Sign Up to like & getrecommendations! Published in 2022 at "Der Nervenarzt"
DOI: 10.1007/s00115-022-01275-5
Abstract: BACKGROUND The recent approval of aduhelm/aducanumab by the US Food and Drug Administration (FDA) in June 2021 raised hopes that further substances against Alzheimer's disease might be approved in the near future. OBJECTIVE The current… read more here.
Keywords: iii studies; phase iii; alzheimer disease; disease ... See more keywords
Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2060924
Abstract: Abstract Objectives Evaluate relationships between changes in dermatologic assessments and quality of life (QoL) measures; quantify dermatologic symptom severity impacts on QoL in patients with psoriatic arthritis (PsA) treated with tofacitinib. Methods Data were from… read more here.
Keywords: patients psoriatic; psoriatic arthritis; life; iii studies ... See more keywords
Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Dermatologic Surgery"
DOI: 10.1097/dss.0000000000003594
Abstract: Supplemental Digital Content is Available in the Text. BACKGROUND AbobotulinumtoxinA (aboBoNT-A) solution is a new ready-to-use formulation developed to reduce preparation time and improve reproducibility of injections. OBJECTIVE To further evaluate treatment of moderate-to-severe glabellar… read more here.
Keywords: placebo; pooled data; treatment; iii studies ... See more keywords
Alectinib exposure-response (ER) in ALK-inhibitor naïve ALK-positive NSCLC patients: Pooled analysis across phase III studies.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e20575
Abstract: e20575 Background: Alectinib superiority to crizotinib has been demonstrated in ALK-inhibitor naïve ALK-positive NSCLC patients (pts) in Phase III studies conducted in Japanese (J-ALEX; JapicCTI-132316) pts receiving alectinib 300 mg BID and global (ALEX; NCT02075840)… read more here.
Keywords: phase iii; alectinib; iii studies; bid ... See more keywords